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Abstract 
The fine-tuning of endocrine homeostasis is regulated by dynamic receptor mediated 
processes. The superfamily of G protein-coupled receptors (GPCRs) have  diverse 
roles in the modulation of all endocrine axes, thus understanding the mechanisms 
underpinning their functionality is paramount for treatment of endocrinopathies. 
Evidence over the last 20 years has highlighted homo and heteromerization as a key 
mode of mediating GPCR functional diversity. This review will discuss the concept of 
GPCR heteromerization and its relevance to endocrine function, detailing in vitro and 
in vivo evidence, and exploring current and potential pharmacological strategies for 
specific targeting of GPCR heteromers in endocrine heath and disease.       
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1. Introduction 
G protein-coupled receptors (GPCRs) are pervasive to most physiological and 
endocrinological processes. Their necessity in maintaining endocrine homeostasis 
makes them a lucrative therapeutic target, with approximately 40% of current 
prescription drugs targeting a GPCR. Resulting pathophysiological disorders caused 
by GPCR dysfunction drives our need to dissect the basic science underpinning the 
complex modalities of GPCR regulation. Furthermore, understanding these 
processes is paramount to more targeted and efficacious next generation 
pharmaceuticals and to personalized medicine approaches (1). 
Homo/heteromerization of GPCR is now a widely accepted modality of how GPCRs 
regulate their physiological functions (1,2). The current evolved model of GPCR 
signaling incorporates the ever-increasing complexity in GPCR signal pathways and 
mechanisms of regulation, to which homo/heteromerization has made a significant 
contribution. Although most studies have documented homo/heteromerization using 
heterologous cell lines, several studies have demonstrated the in vivo significance of 
these receptor-receptor interactions. Such complexity in receptor regulation provides 
key mechanism/s for the multiple and dynamic roles these receptors play in vivo.  
This review will discuss the functional and in vivo evidence for GPCR heteromers in 
endocrine systems. We will describe the criteria for assessing and classifying GPCR 
heteromers, review their known functional impact from both in vitro and in vivo 
studies of these hetero-complexes on endocrine function. 
 
2. Detecting and classifying GPCR heteromers-an overview  
GPCR heteromerization is defined as a macromolecule complex composed of at 
least two receptor units, with biochemical properties that are demonstrably different 
from those of its individual components (2). With an increase in the number of reports 
identifying GPCR heteromers, the resulting challenges in distinguishing the 
difference between receptors localised to the same cell undergoing functional cross-
talk, versus receptors complexed as physiologically relevant heteromers became an 
important distinction. Thus, three consensus criteria were published by the 
International Union of Basic and Clinical Pharmacology to facilitate the classification 
of true GPCR heteromers (3). The first of these criteria concerns the requirement for 
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evidence of physical receptor-receptor interactions in native or primary tissue. 
Traditionally, methods such as co-immunoprecipitation and resonance energy 
transfer techniques (4-8) have been used to demonstrate receptor-receptor 
interactions and hence the proximal existence of heteromers. Recent technological 
advances in super-resolution and single molecule imaging present an innovative 
methodology for detecting GPCR heteromers. Techniques such as fluorescent 
correlation spectroscopy (9,10), single particle tracking via total internal-reflection 
fluorescent microscopy (11-13) and localization microscopy techniques such as 
photoactivated localization microscopy (14,15) have been utilised to identify GPCR 
heteromers and homomers. Likewise, proximity ligation assays (PLA), also provide a 
mechanism for identifying heteromers in native tissues (16).    
The second consensus criteria requires there to be heteromer-specific properties, be 
it a change in the pharmacology of the receptors via G protein specificity or allosteric 
binding properties, or ligands that are heteromer-specific. This is demonstrated via 
classical biochemical, pharmacological and cell signaling techniques to determine 
changes in ligand binding, G protein-dependent and G protein-independent signal 
activation. The third criteria necessitates the requirement for the direct physiological 
evidence for the importance of the identified heteromer. Methodology used to 
determine this include RNA interference or in vivo studies to introduce genetic 
modifications in receptor protomers participating in the heteromer. If the 
transmembrane interface is known, expression or incubation of cell permeable 
peptides corresponding to the transmembrane region have been employed in vitro 
and in vivo. Thus, confirming the physiological requirement for the heteromer (2,3). 
In practice, there are very few identified heteromers that fit all three criteria; with 
criteria three often the hardest to fulfil given that most functional heteromers have 
been identified using heterologous cell lines. Therefore, fulfilment of two out of three 
of the criteria are required for the acceptance of a GPCR heteromer. With respect to 
endocrine systems, most identified GPCR heteromers that fulfil all three inclusion 
criteria are neuroendocrine in nature. The functional significance of which will be 
discussed in further detail. 
 
3. Impact of GPCR heteromers on receptor activity in endocrine systems 
The canonical view of GPCR signaling has evolved from a ligand binding to a single 
monomeric receptor that activates a single heterotrimeric G protein, to one of 
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growing complexity. GPCR homo/heteromerization provides a modality whereby 
receptors can mediate multiple functions via modulating receptor trafficking (both 
exo- and endocytosis), ligand specificity and functional selectivity. In obligatory 
heteromers such as the GABAB1 and GABAB2 receptors, (also observed with the 
sweet and umami taste receptors (17-19)), the functional significance of 
heteromerization is required for cell surface expression of both receptors, as well as 
G protein-coupling (20-22), via transactivation of GABAB1-GABAB2 heteromers. 
However, identifying the functional significance of GPCR heteromers are not always 
essential to all functions mediated by a specific receptor. That said, heteromer 
formation can increase the spectrum of ligand recognition and signal outcomes of a 
receptor. One common mode of regulation within a heteromer is via allosterism, the 
outcome of which can lead to distinct functional responses to that of the individual 
receptors. Broadly speaking, allosteric interactions within heteromers can lead to 
three different functional outcomes:  
1. Ligand binding. Ligand binding within a heteromer results in either positive or 
negative cooperativity exerted on the neighbouring receptor(s) within the 
heteromer.  
2. G protein recruitment. G protein selectivity may change or exert differential 
preferences between heteromeric and homomeric complexes.  
3. G-protein independent mechanisms via -arrestin recruitment. The heteromer 
may favour or acquire G protein-independent functionality via -arrestin 
recruitment. 
Many GPCR heteromers have been shown to have direct roles in endocrine 
homeostasis, impacting metabolism, reproduction, nutritional status and stress 
responses (Table 1). The functional significance of such heteromers has largely been 
dissected using heterologous cell lines, examples of which will be discussed below. 
 
3.1 Metabolism and nutrition 
Endocrine-mediated feedback for the control of satiety and appetite is essential for 
maintaining metabolic homeostasis. Key pathways that regulate appetite stimulation 
and feeding are mediated via the growth hormone secretagogue receptor (GHSR). 
GHSR is expressed within various hypothalamic nuclei involved in food intake and 
reward-seeking behaviour (reviewed by (23)), and thus has been suggested to be a 
central player in regulating metabolic homeostasis in both a ligand-dependent (via 
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Ghrelin) and -independent manner, via intrinsic basal GSHR activity (23,24). Several 
studies have demonstrated GHSR to heteromerize with other GPCRs that also 
regulate metabolic status (23). Indeed, heteromerization of GSHR and the 
melanocortin-3 receptor (MC3R) was identified by fluorescence resonance energy 
transfer (FRET) (25), with immunohistochemical and in situ studies co-localizing 
GHSR and MC3R to the arcuate nucleus of the hypothalamus. The functional 
significance of the GHSR/MC3R heteromers examined in vitro via co-expression of 
GHSR and MC3R in COS-7 and HEK293 cells, showed that GSHR/MC3R 
heteromers may enhance MC3R-dependent cAMP accumulation yet decrease basal 
and ligand-induced GHSR activity. Moreover, the enhanced MC3R activity observed 
was dependent on the decrease in basal GHSR activity, suggesting positive and 
negative allosteric regulation between MC3R and GHSR protomers to create 
functionally asymmetric complexes (26).  
 
Heteromers of the Class B GPCR family have been suggested to have roles in 
glucose homeostasis. Ligand-dependent BRET screening of the glucagon receptor 
family heteromeric and homomeric interactions in HEK293 cells, showed glucagon-
like peptide-1 (GLP-1)-dependent heteromer formation between GLP1 and gastric-
inhibitory polypeptide receptors (GIPR). This heteromeric association was GLP-1-
specific, with reversal of GLP-1/GIPR association observed with titration of GIPR. 
Functionally, a change in the activity of the GLP-1R was also observed in terms of 
calcium response, and -arrestin recruitment (27). There has also been recent 
evidence for functional cross-talk between Gs and Gq-coupled receptors in the 
regulation of long chain fatty acid mediated incretin secretion. Recent findings have 
shown that GPR40-mediated GLP-1 release by colonic enteroendocrine cells 
requires high cAMP levels, achieved via the bile acid receptor TGR5 or GPR119-
dependent Gs activity (28,29). Although these studies suggest functional cross talk 
at the level of G-protein dependent signaling between Gq- and Gs-coupled 
GPCRs, whether this is mediated via heteromerization remains to be demonstrated.   
 
Heteromers of vasopressin 1b receptor (V1bR) and corticotrophin releasing hormone 
receptors (CRHR) have also been demonstrated to be functionally important for 
mediating the biological functions of their respective hormones. In HEK293 cells, 
V1bR/CRHR heteromers were shown to act to synergistically enhance the G protein-
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dependent signal responses. Such enhancement of vasopressin and CRH function 
could underpin their importance in mediating metabolic responses via 
adrenocorticotrophin hormone release and insulin secretion (30). 
 
3.2 Reproduction 
The gonadotropin receptors follicle-stimulating hormone receptor (FSHR) and 
luteinizing hormone receptor (LHR) are essential for reproduction (31,32). Expressed 
in specialised cellular compartments of the testis and ovary, FSHR and LHR 
coordinate gonadal steroidogenesis and the production and/or maturation of germ 
cells (31,32). Both FSHR and LHR have been shown to form homomers in vitro (15, 
33-38). Moreover, using a functional complementation approach, we have shown 
that transgenic co-expression of ligand-binding deficient LHR and signal deficient 
LHR could rescue the infertile phenotype of LHR knockout males (33), thus 
demonstrating that homomerization is a physiologically relevant mode of LHR 
function.   Recent studies have also shown that the FSHR and LHR can 
heteromerize (39,40).  Heteromerization has been demonstrated using BRET (40) 
and fluorescent correlation spectroscopy (39), moreover, heteromerization appears 
to alter the pharmacology of the LHR and FSHR by enhancing ligand disassociation, 
and negatively regulating cAMP production (40). LHR/FSHR heteromerization is only 
physiologically relevant to female reproduction, where co-expression of FSHR and 
LHR in granulosa cells primarily occurs during the peri-ovulatory period, (41). A 
defined window of co-expression suggests a role for the heteromer in modulating the 
pleurotrophic actions of LHR during ovulation. Recent studies have also found that 
co-treatment of FSH with either hCG or LH can potentiate their respective effects on 
steroidogenesis and apoptosis (42). Integration of these findings into the 
physiological role of LHR and FSHR remains to be demonstrated.  
 
4. In vivo role of GPCR heteromerization to health and disease 
Although many GPCR heteromers have been identified, the in vivo physiological 
role(s) of many remains speculative and inferred from heterologous cell types or 
primary cell cultures. This is mainly due to the technical difficulties often encountered 
with identifying endogenous receptors. However, with recent methodological 
advances, such as proximity ligation assays and time-resolved FRET, several 
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studies have made significant head-way in identifying GPCR heteromers in vivo, and 
deciphering their functional roles. 
 
Recent work has identified two novel heteromers of dopamine D4 receptor 
(D4R)/1B adrenergic receptors (1BR) and dopamine D4/1 adrenergic receptors 
(1R), the formation of which is controlled by circadian rhythm and the light-dark 
cycle. A study by Gonzalez et al, identified D4R-1BR and D4R-1R heteromers in 
primary pinealocytes and pineal glands, via proximity ligation assay (43), and that 
formation of D4R-adrenergic receptor heteromers was controlled by the expression 
level of D4R, with increased heteromer formation at sunrise, and decreased/little 
heteromer formation at sunset. Pharmacologically, adrenergic receptor-D4R 
heteromers cross-antagonised the release of melatonin via the regulation of the 
synthesis and secretion of serotonin, the precursor of melatonin. Thus, low level 
heteromer formation correlated with increased release of melatonin at sunset, and 
low melatonin release and high heteromer formation at sunrise (43), clearly exhibiting 
how key physiological functions are intricately controlled at the level of heteromer 
formation.   
 
Isoforms of the dopamine receptor family have been shown to heteromerize with 
GHSR. Via TR-FRET and FRET, dopamine D2 receptor (D2R)/GHSR heteromers 
were demonstrated in vivo within the hypothalamus (44). Moreover, D2R/GHSR 
heteromers amplified the anorexigenic effects of D2R.  Using cabergoline, the D2R-
selective agonist, a dose-dependent suppression of food intake in wild-type and 
ghrelin knock-out mice was observed, however, there was no effect on food intake in 
GHSR knock-out mice. These data illustrate that the anorexigenic effects of D2R are 
augmented by GHSR, presenting a possible avenue for therapeutic interventions in 
food intake disorders (44).  
 
GSHR and somatostatin 5a (SST5a) receptors have been demonstrated via TR-
FRET in  islet cells of the pancreas. Heteromerization of GHSR and SST5a 
changed the G protein-coupling preference of GSHR to Gi, mediating ghrelin and 
somatostatin-induced inhibition of glucose-stimulated insulin secretion. Moreover, the 
degree of heteromerization detected was ligand-regulated, with high ghrelin and low 
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somatostatin increasing heteromer formation, as detected via BRET (45). This, in 
turn regulated the canonical (GHSR- Gq coupling) versus non-canonical (GHSR-
Gi coupling) signaling detected. Thus, suggesting a role for the GSHR/SST5a 
heteromer formation and activity in fine-tuning and regulating  islet-cell mediated 
insulin secretion (45). 
 
A further study has also elucidated the in vivo roles of GHSR/GPR83 heteromers.  
GPR83 is an orphan GPCR expressed within hypothalamic nuclei where it controls 
energy balance, and co-localizes with GHSR in the arcuate nucleus. In vitro analysis 
using HEK293 cells demonstrated heteromerization of GPR83 and GHSR via BRET 
(46). Moreover, in vivo exploration of the physiological role of the GPR83/GHSR 
heteromers using transgenic knock-out approaches showed that GPR83 knockout 
mice were protected from weight gain when fed on high-fat diets, despite 
hyperphagia (46) demonstrating an intriguing role for GPR83 and GHSR heteromers 
in both feeding behaviour and energy metabolism. 
 
In recent years, several heteromers have been identified with relevance to 
fetal/maternal health. The intriguing formation of angiotensin 1 receptor  (AT1R) and 
bradykinin 2 receptor (B2R) heteromers were implicated in the pathophysiological 
development of pre-eclampsia (47,48). The expression of AT1R-B2R heteromers 
were more abundant on platelets and omental vessels isolated from women with pre-
eclampsia, with increased heteromer formation due to the upregulated expression of 
B2R, resulting in the elevation of angiotensin II-dependent Gq activity.    
'Heteromerization can provide a mechanism underlying how the multifaceted 
functional roles of a single receptor subtype can be mediated. Thus, the identification 
of GPCR heteromers in vitro, and the functional and physiological validation of 
heteromers in vivo identifies potential novel therapeutic interventions and drug 
targets.  
   
5. Pharmacological exploitation of GPCR heteromers 
GPCR heteromers have attracted significant attention from the pharmaceutical 
industry due to their potential to address the non-specific effects of drugs thought to 
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result from heteromerization, or to exploit the novel properties of heteromers in the 
design of new therapeutics. The unique biochemical signature of GPCR heteromers, 
be it a change in trafficking, pharmacology or signaling properties, provide a platform 
for screening and differential drug targeting. Indeed, well-characterized GPCR 
heteromers have already been targeted in the development for novel treatment of 
Parkinson’s disease, addiction, schizophrenia, depression and chronic kidney 
disease. (49). 'The main strategies to target GPCR heteromers to date are to activate 
the heteromer specifically via bivalent ligands, using small molecules that target 
heteromer-specific allosteric binding pockets, or inhibit heteromer function via a drug 
combination approach, or multifunctional ligands. 
 
5.1 Specific activation of GPCR heteromers 
Drug development strategies to specifically target GPCR heteromers focus on 
conditions where targeting of the heteromer has beneficial activities over the 
homomer. To date there are few known ligands with proven heteromer-specific 
activity in vivo. The best described examples are those targeting the opioid 
receptors. For example, CYM51010 is a repurposed compound thought to be a 
specific ligand for the  opioid receptor heteromer (50). Interestingly this 
compound is a biased ligand to the -arrestin pathway for these heteromers and 
activates analgesic responses similarly to morphine, yet with reduced tolerance 
under chronic treatment. The binding site of this compound may be an allosteric site 
unique to the heteromer, or at least distinct from each orthosteric site in each 
protomer, as the -opioid receptor antagonist only partially inhibits the in vitro activity 
of the heteromer.  Furthermore, the in vivo action of CYM51010 (but not morphine), 
was blocked by a heteromer-specific antibody, showing specificity for the heteromer-
specific actions (50). 
 
Bivalent ligands, in the context of GPCR homo/heteromerization, consist of a 
compound that is selective for one protomer linked by a spacer arm to a compound 
selective for its partner protomer. These are distinct from bitopic ligands that are 
compounds able to interact with orthosteric and allosteric sites. Although bitopic (or 
dualsteric) ligands have been designed based on a monomeric GPCR model, it is 
certainly possible that these ligands could be designed to be heteromer-specific, 
although this has not yet been explored for this class of compounds. Bivalent ligands 
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are thought to target and stabilize pre-formed/constitutive heteromers rather than 
induce heteromerization (51) and have been used as tools to understand the 
functional significance of specific GPCR heteromers. To date many have been 
developed towards heteromers containing the μOR. One interesting example is a 
bivalent ligand that targets the heteromer of μOR/metabotropic glutamate receptor 5 
for treatment of chronic inflammatory pain. The compound identified was a μOR 
agonist coupled to a metabotropic glutamate receptor 5 antagonist and also 
illustrated that highly defined spacer lengths were key to its activity in vivo (52).  In 
the context of endocrine systems, bivalent ligands have provided a useful tool to 
support the clinical and therapeutic relevance of the D2R dopamine receptor/ 
somatostatin SST2 receptors in acromegaly. These heteromers are expressed in 
GH-secreting pituitary tumors and have enhanced Gi-signaling activity over their 
homomeric counterparts (53,54). Employment of bivalent ligands, however, 
demonstrated that targeting both these receptors can effectively inhibit GH and 
prolactin secretion from GH-secreting pituitary adenomas, more effectively than their 
response to somatostatin receptor antagonist octreotide (55,56). Bivalent ligands 
have also been developed for the gonadotrophin hormone receptors in order to 
improve receptor specificity of allosteric low molecular weight compounds to these 
receptors. Although the study did not assess the compound in the context of 
LHR/FSHR heterodimers, a small molecular activator of both LHR and FSHR was 
made more specific to LHR (although resulted in a loss of potency) by linking it with 
an FSHR-specific negative allosteric modulator (57,58) 
 
5.2 Specific pharmacological inhibition of GPCR heteromer function 
GPCR heteromers may play a role in the off-target effect of certain drugs and/or 
have a demonstrated role in human disease, thus selective inhibition of these 
complexes has been achieved via combination therapy or bi/multifunctional ligands. 
A combination therapy approach relevant for endocrine systems is currently in Phase 
2 clinical studies for chronic kidney disease. This is based on a therapy to target 
chemokine receptor CCR2/ angiotensin II type 1A receptor heteromers, repurposing 
two known antagonists for CCR2 and angiotensin 1A receptor, termed DMX-200 
(59). 
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Bifunctional or multifunctional peptide ligands could represent an alternate strategy to 
block action of specific heteromers. These peptide ligands possess agonist activity to 
one GPCR and antagonistic properties to another. For example, bifunctional ligands 
that are agonistic at  and/or -opioid receptors yet antagonistic at pro-nociceptive 
cholecystokinin receptor (60) or substance P neurokinin-1 receptor (61), are thought 
to create a potent analgesic with fewer side effects than morphine (62), however it is 
unknown whether such compounds target heteromers of these receptors.  
 
6. Perspectives 
How individual cells integrate and decode multiple signals from an array of distinct 
receptors remains an outstanding question. The evidence to date strongly supports a 
significant role for GPCR heteromerization in the cellular signaling network, and the 
downstream significance of these associations in both health and disease. The 
number of reports of GPCR heteromers across diverse physiological and 
pathophysiological systems has dramatically increased, particularly as the 
technology to identify and characterise these heteromers- from the single molecule to 
its in vivo function- have been developed. Although this field of GPCR biology has 
driven continuous debate on the significance of such interactions, the communication 
of a standardized framework to study GPCR heteromers (2,63) and tools to 
demonstrate in vivo significance will contribute to our evolving models of GPCR 
signaling. 
Current challenges are to understand how to effectively exploit this complexity, 
although certain strategies are showing real promise, as discussed above. 
Furthermore, what is the extent of GPCR heteromerization and how does it 
contribute to the overall signal crosstalk in cells that express hundreds of distinct 
GPCRs exposed to multiple ligands? This latter question highlights a functional 
requirement for crosstalk via heteromerization of GPCRs that contain more than two 
GPCRs, considering not only oligomeric composition, but also that a heteromer may 
contain more than two different GPCRs. There is increasing evidence that for certain 
GPCRs heterotetramers may be the functional form, e.g. D2R-A2A and D2-D3 
dopamine receptors, containing equivalent ratios of each GPCR, i.e. association of 
two homodimers (64). This is thought to provide a platform for coupling of distinct G 
proteins, and certainly this is consistent with the idea that functionally asymmetric 
GPCR oligomers could regulate G protein signal strength (15). The idea that more 
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than two GPCRs form heteromers has been demonstrated for chemokine receptors 
(heteromer of CCR2-CCR5-CXCR4) (65). Such complex associations could be 
highly significant for endocrine systems where extensive signal crosstalk is exposed 
to a highly dynamic extracellular environment. Despite the recent technical advances, 
a missing piece of the GPCR signaling puzzle is crystal structure information of a 
heteromeric GPCR complex. The explosion of available crystal structures of GPCRs 
has transformed drug design strategies for the GPCR monomer model, and although 
crystal structures of homodimers (66-67) and homo-oligomers (68) have been 
identified, heteromeric structures would provide unprecedented information, not only 
on interfaces, but unique heteromer-specific targeting sites for structure-based drug 
discovery. With the generation of antibodies that target GPCR heteromers and the 
use of nanobodies in GPCR research (69-76), there is a real technical possibility of 
creating tools to aid stabilisation of such structures for crystallization. Likewise there 
is increase interested in immunotherapy pathways, particularly in cancer, and whilst 
there are no current approved GPCR antibody drugs, antibodies specific to GPCR 
heteromers have been generated (77). 
Overall, GPCR heteromers are becoming increasingly accepted as part of the GPCR 
signalosome, which is integrated in to an even more complex cellular network. As the 
signal wires mediated by GPCR heteromers are untangled, this will provide new 
insights and therapeutic avenues in to the roles of these GPCR complexes in 
endocrine systems. 
 
Acknowledgements 
This work was supported by Biotechnology and Biological Sciences Research 
Council Grant (BB/1008004/1) and Genesis Research Trust. 
 
References  
1. Ferre, S., Casado, V., Devi, L. A., Filizola, M., Jockers, R., Lohse, M. J., 
Milligan, G., Pin, J. P., and Guitart, X. (2014) G protein-coupled receptor 
oligomerization revisited: functional and pharmacological perspectives. 
Pharmacological reviews 66, 413-434 
 
2. Gomes, I., Ayoub, M. A., Fujita, W., Jaeger, W. C., Pfleger, K. D., and Devi, L. 
A. (2016) G Protein-Coupled Receptor Heteromers. Annu Rev Pharmacol 
Toxicol 56, 403-425 
 
 
 
14 
 
3. Kenakin, T., Agnati, L. F., Caron, M., Fredholm, B., Guidoli, D., Kobilka, B., 
Lefkowitz, R. W., Lohse, M., Woods, A., and Fuxe, K. (2010) International 
Workshop at the Nobel Forum, Karolinska Institutet on G protein-coupled 
receptors: finding the words to describe monomers, oligomers, and their 
molecular mechanisms and defining their meaning. Can a consensus be 
reached? J Recept Signal Transduct Res 30, 284-286 
 
4. Angers, S., Salahpour, A., Joly, E., Hilairet, S., Chelsky, D., Dennis, M., and 
Bouvier, M. (2000) Detection of beta 2-adrenergic receptor dimerization in 
living cells using bioluminescence resonance energy transfer (BRET). 
Proceedings of the National Academy of Sciences of the United States of 
America 97, 3684-3689 
 
5. Hounsou, C., Margathe, J. F., Oueslati, N., Belhocine, A., Dupuis, E., Thomas, 
C., Mann, A., Ilien, B., Rognan, D., Trinquet, E., Hibert, M., Pin, J. P., Bonnet, 
D., and Durroux, T. (2015) Time-resolved FRET binding assay to investigate 
hetero-oligomer binding properties: proof of concept with dopamine D1/D3 
heterodimer. ACS Chem Biol 10, 466-474 
 
6. Albizu, L., Cottet, M., Kralikova, M., Stoev, S., Seyer, R., Brabet, I., Roux, T., 
Bazin, H., Bourrier, E., Lamarque, L., Breton, C., Rives, M. L., Newman, A., 
Javitch, J., Trinquet, E., Manning, M., Pin, J. P., Mouillac, B., and Durroux, T. 
(2010) Time-resolved FRET between GPCR ligands reveals oligomers in 
native tissues. Nature chemical biology 6, 587-594 
 
7. Pfleger, K. D., Dalrymple, M. B., Dromey, J. R., and Eidne, K. A. (2007) 
Monitoring interactions between G-protein-coupled receptors and beta-
arrestins. Biochemical Society transactions 35, 764-766 
 
8. Ramsay, D., Kellett, E., McVey, M., Rees, S., and Milligan, G. (2002) Homo- 
and hetero-oligomeric interactions between G-protein-coupled receptors in 
living cells monitored by two variants of bioluminescence resonance energy 
transfer (BRET): hetero-oligomers between receptor subtypes form more 
efficiently than between less closely related sequences. The Biochemical 
journal 365, 429-440 
 
9. Mazurkiewicz, J. E., Herrick-Davis, K., Barroso, M., Ulloa-Aguirre, A., Lindau-
Shepard, B., Thomas, R. M., and Dias, J. A. (2015) Single-molecule analyses 
of fully functional fluorescent protein-tagged follitropin receptor reveal 
homodimerization and specific heterodimerization with lutropin receptor. 
Biology of reproduction 92, 100 
 
10. Zakrys, L., Ward, R. J., Pediani, J. D., Godin, A. G., Graham, G. J., and 
Milligan, G. (2014) Roundabout 1 exists predominantly as a basal dimeric 
complex and this is unaffected by binding of the ligand Slit2. The Biochemical 
journal 461, 61-73 
 
11. Kasai, R. S., Suzuki, K. G., Prossnitz, E. R., Koyama-Honda, I., Nakada, C., 
Fujiwara, T. K., and Kusumi, A. (2011) Full characterization of GPCR 
monomer-dimer dynamic equilibrium by single molecule imaging. The Journal 
of cell biology 192, 463-480 
 
12. Hern, J. A., Baig, A. H., Mashanov, G. I., Birdsall, B., Corrie, J. E., Lazareno, 
S., Molloy, J. E., and Birdsall, N. J. (2010) Formation and dissociation of M1 
muscarinic receptor dimers seen by total internal reflection fluorescence 
 
 
 
15 
 
imaging of single molecules. Proceedings of the National Academy of 
Sciences of the United States of America 107, 2693-2698 
 
13. Calebiro, D., Rieken, F., Wagner, J., Sungkaworn, T., Zabel, U., Borzi, A., 
Cocucci, E., Zurn, A., and Lohse, M. J. (2013) Single-molecule analysis of 
fluorescently labeled G-protein-coupled receptors reveals complexes with 
distinct dynamics and organization. Proceedings of the National Academy of 
Sciences of the United States of America 110, 743-748 
 
14. Scarselli, M., Annibale, P., and Radenovic, A. (2012) Cell type-specific beta2-
adrenergic receptor clusters identified using photoactivated localization 
microscopy are not lipid raft related, but depend on actin cytoskeleton 
integrity. The Journal of biological chemistry 287, 16768-16780 
 
15. Jonas, K. C., Fanelli, F., Huhtaniemi, I. T., and Hanyaloglu, A. C. (2015) 
Single molecule analysis of functionally asymmetric G protein-coupled 
receptor (GPCR) oligomers reveals diverse spatial and structural assemblies. 
The Journal of biological chemistry 290, 3875-3892 
 
16. Gonzalez, S., Moreno-Delgado, D., Moreno, E., Perez-Capote, K., Franco, R., 
Mallol, J., Cortes, A., Casado, V., Lluis, C., Ortiz, J., Ferre, S., Canela, E., 
and McCormick, P. J. (2012) Circadian-related heteromerization of adrenergic 
and dopamine D(4) receptors modulates melatonin synthesis and release in 
the pineal gland. PLoS Biol 10, e1001347 
 
17.  Nelson G, Hoon MA, Chandrashekar J, Zhang Y, Ryba NJ, Zuker CS. (2001) 
Mammalian sweet taste receptors. Cell. 106(3):381-90 
 
18.  Nelson G, Chandrashekar J, Hoon MA, Feng L, Zhao G, Ryba NJ, Zuker CS 
(2002) An amino-acid taste receptor. Nature 416(6877):199-202 
 
19.  Xu H, Staszewski L, Tang H, Adler E, Zoller M, Li X. (2004) Different 
functional roles of T1R subunits in the heteromeric taste receptors. Proc Natl 
Acad Sci U S A. 101(39):14258-63 
 
20. Kaupmann, K., Malitschek, B., Schuler, V., Heid, J., Froestl, W., Beck, P., 
Mosbacher, J., Bischoff, S., Kulik, A., Shigemoto, R., Karschin, A., and Bettler, 
B. (1998) GABA(B)-receptor subtypes assemble into functional heteromeric 
complexes. Nature 396, 683-687 
21.  Duthey B, Caudron S, Perroy J, Bettler B, Fagni L, Pin JP, Prézeau L. (2001) 
A single subunit (GB2) is required for G-protein activation by the 
heterodimeric GABA(B) receptor. J. Biol. Chem. 277(5):3236-41 
22.  Pin JP, Kniazeff J, Binet V, Liu J, Maurel D, Galvez T, Duthey B, Havlickova 
M, Blahos J, Prézeau L, Rondard P. (2004) Activation mechanism of the 
heterodimeric GABA(B) receptor. Biochem Pharmacol. 68(8):1565-72 
23.  Wellman M, Abizaid A. (2015) Growth Hormone Secretagogue Receptor 
Dimers: A New Pharmacological Target(1,2,3). eNeuro.2(2). pii:  
 
24.  Yin Y, Li Y, Zhang W. (2014) The growth hormone secretagogue receptor: its 
intracellular signaling and regulation. Int J Mol Sci. 15(3):4837-55 
 
 
 
 
16 
 
25.  Rediger A, Tarnow P, Bickenbach A, Schaefer M, Krude H, Gruters A, 
Biebermann H (2009) Heterodimerization of hypothalamic G-protein-coupled 
receptors involved in weight regulation. Obes Facts. 2(2):80-6 
 
26.  Rediger A, Piechowski CL, Yi CX, Tarnow P, Strotmann R, Grüters A, Krude 
H, Schöneberg T, Tschöp MH, Kleinau G, Biebermann H (2011) Mutually 
opposite signal modulation by hypothalamic heterodimerization of ghrelin and 
melanocortin-3 receptors. J Biol Chem. 286(45):39623-31 
 
27.  Schelshorn D, Joly F, Mutel S, Hampe C, Breton B, Mutel V, Lütjens R. 
(2012) Lateral allosterism in the glucagon receptor family: glucagon-like 
peptide 1 induces G-protein-coupled receptor heteromer formation. Mol 
Pharmacol. 81(3):309-18 
 
28.  Hauge M, Ekberg JP, Engelstoft MS, Timshel P, Madsen AN, Schwartz TW 
(2016) Gq and Gs signaling acting in synergy to control GLP-1 secretion. Mol 
Cell Endocrinol. pii: S0303-7207(16)30493-2 
 
29.  Hauge M, Vestmar MA, Husted AS, Ekberg JP, Wright MJ, Di Salvo J, 
Weinglass AB, Engelstoft MS, Madsen AN, Lückmann M, Miller MW, Trujillo 
ME, Frimurer TM, Holst B, Howard AD, Schwartz TW. (2014) GPR40 
(FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust 
incretin secretagogue action ex vivo and in vivo. Mol Metab. 4(1):3-14. 
 
30.  Murat B, Devost D, Andrés M, Mion J, Boulay V, Corbani M, Zingg HH, 
Guillon G (2012) V1b and CRHR1 receptor heterodimerization mediates 
synergistic biological actions of vasopressin and CRH. Mol Endocrinol. 
26(3):502-20 
 
31.  Jonas KC, Oduwole OO, Peltoketo H, Rulli SB, Huhtaniemi IT (2014) Mouse 
models of altered gonadotrophin action: insight into male reproductive 
disorders. Reproduction. 48(4):R63-70 
 
32.  Peltoketo H, Rivero-Müller A, Ahtiainen P, Poutanen M, Huhtaniemi (2010) 
Consequences of genetic manipulations of gonadotrophins and 
gonadotrophin receptors in mice. Ann Endocrinol (Paris). 71(3):170-6 
 
33.  Rivero-Müller A, Chou YY, Ji I, Lajic S, Hanyaloglu AC, Jonas K, Rahman N, 
Ji TH, Huhtaniemi I (2010) Rescue of defective G protein-coupled receptor 
function in vivo by intermolecular cooperation. Proc Natl Acad Sci U S A. 
107(5):2319-24 
 
34.  Guan R, Wu X, Feng X, Zhang M, Hébert TE, Segaloff DL (2010) Structural 
determinants underlying constitutive dimerization of unoccupied human 
follitropin receptors. Cell Signal. 22(2):247-56 
 
35.  Guan R, Feng X, Wu X, Zhang M, Zhang X, Hébert TE, Segaloff DL (2009) 
Bioluminescence resonance energy transfer studies reveal constitutive 
dimerization of the human lutropin receptor and a lack of correlation between 
receptor activation and the propensity for dimerization. J Biol Chem. 
284(12):7483-94 
36. Urizar E, Montanelli L, Loy T, Bonomi M, Swillens S, Gales C, Bouvier M, 
Smits G, Vassart G, Costagliola S. (2005) Glycoprotein hormone receptors: 
 
 
 
17 
 
link between receptor homodimerization and negative cooperativity. EMBO J. 
24(11):1954-64. 
 
37.  Tao YX, Johnson NB, Segaloff DL (2004) Constitutive and agonist-dependent 
self-association of the cell surface human lutropin receptor. J Biol Chem. 
279(7):5904-14 
38.  Horvat RD, Barisas BG, Roess DA (2001) Luteinizing hormone receptors are 
self-associated in slowly diffusing complexes during receptor desensitization. 
Mol Endocrinol. 5(4):534-42. 
39.  Mazurkiewicz JE, Herrick-Davis K, Barroso M, Ulloa-Aguirre A, Lindau-
Shepard B, Thomas RM, Dias JA. (2015) Single-molecule analyses of fully 
functional fluorescent protein-tagged follitropin receptor reveal 
homodimerization and specific heterodimerization with lutropin receptor. Biol 
Reprod. 92(4):100 
40.  Feng X, Zhang M, Guan R, Segaloff DL (2013) Heterodimerization between 
the lutropin and follitropin receptors is associated with an attenuation of 
hormone-dependent signaling. Endocrinology. 154(10):3925-30 
41.  Jeppesen JV, Kristensen SG, Nielsen ME, Humaidan P, Dal Canto M, Fadini 
R, Schmidt KT, Ernst E, Yding Andersen C (2012) LH-receptor gene 
expression in human granulosa and cumulus cells from antral and 
preovulatory follicles. J Clin Endocrinol Metab. 97(8):E1524-31 
42.  Casarini L, Riccetti L, De Pascali F, Nicoli A, Tagliavini S, Trenti T, La Sala 
GB, Simoni M. (2016) Follicle-stimulating hormone potentiates the 
steroidogenic activity of chorionic gonadotropin and the anti-apoptotic activity 
of luteinizing hormone in human granulosa-lutein cells in vitro. Mol Cell 
Endocrinol. 422:103-14 
43.  González S, Moreno-Delgado D, Moreno E, Pérez-Capote K, Franco R, 
Mallol J, Cortés A, Casadó V, Lluís C, Ortiz J, Ferré S, Canela E, McCormick 
PJ. (2012) Circadian-related heteromerization of adrenergic and dopamine D₄ 
receptors modulates melatonin synthesis and release in the pineal gland. 
PLoS Biol. 10(6):e1001347 
44.  Kern A, Albarran-Zeckler R, Walsh HE, Smith RG. (2012) Apo-ghrelin 
receptor forms heteromers with DRD2 in hypothalamic neurons and is 
essential for anorexigenic effects of DRD2 agonism. Neuron. 73(2):317-32 
45.  Park S, Jiang H, Zhang H, Smith RG (2012) Modification of ghrelin receptor 
signaling by somatostatin receptor-5 regulates insulin release. Proc Natl Acad 
Sci U S A. 109(46):19003-8 
46.  Müller TD, Müller A, Yi CX, Habegger KM, Meyer CW, Gaylinn BD, Finan B, 
Heppner K, Trivedi C, Bielohuby M, Abplanalp W, Meyer F, Piechowski CL, 
Pratzka J, Stemmer K, Holland J, Hembree J, Bhardwaj N, Raver C, Ottaway 
N, Krishna R, Sah R, Sallee FR, Woods SC, Perez-Tilve D, Bidlingmaier M, 
Thorner MO, Krude H, Smiley D, DiMarchi R, Hofmann S, Pfluger PT, Kleinau 
G, Biebermann H, Tschöp MH. (2013) The orphan receptor Gpr83 regulates 
systemic energy metabolism via ghrelin-dependent and ghrelin-independent 
mechanisms. Nat Commun. 4:1968 
 
 
 
18 
 
47. S. AbdAlla, H. Lother, A. el Massiery, U. Quitterer (2001) Increased AT(1) 
receptor heterodimers in preeclampsia mediate enhanced angiotensin II 
responsiveness Nat Med, 7 : 1003–1009 
48.  U. Quitterer, H. Lother, S. AbdAlla (2004) AT1 receptor heterodimers and 
angiotensin II responsiveness in preeclampsia Semin Nephrol, 24: 115–119 
49. Guidolin D, Agnati LF, Marcoli M, Borroto-Escuela DO, Fuxe K. (2015) G-
protein-coupled receptor type A heteromers as an emerging therapeutic 
target. Expert Opin Ther Targets. 19(2):265-83 
50. Gomes I, Fujita W, Gupta A, Saldanha SA, Negri A, Pinello CE, Eberhart C, 
Roberts E, Filizola M, Hodder P, Devi LA. (2013) Identification of a μ-δ opioid 
receptor heteromer-biased agonist with antinociceptive activity. Proc Natl 
Acad Sci U S A. 110(29):12072-7 
51.  Berque-Bestel I1, Lezoualc'h F, Jockers R (2008) Bivalent ligands as specific 
pharmacological tools for G protein-coupled receptor dimers Curr Drug 
Discov Technol. 5(4):312-8. 
52. Akgün E1, Javed MI, Lunzer MM, Smeester BA, Beitz AJ, Portoghese PS. 
(2013) Ligands that interact with putative MOR-mGluR5 heteromer in mice 
with inflammatory pain produce potent antinociception. Proc Natl Acad Sci U 
S A. 110(28):11595-9 
53.  Colao A, Filippella M, Pivonello R, Di Somma C, Faggiano A, Lombardi 
G.(2007) Combined therapy of somatostatin analogues and dopamine 
agonists in the treatment of pituitary tumours. Eur J Endocrinol. 156 Suppl 
1:S57-63 
54. Rocheville M1, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC (2000) 
Receptors for dopamine and somatostatin: formation of hetero-oligomers with 
enhanced functional activity. Science. 288(5463):154-7 
55.  Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, 
Enjalbert A, Culler MD (2005) Efficacy of chimeric molecules directed towards 
multiple somatostatin and dopamine receptors on inhibition of GH and 
prolactin secretion from GH-secreting pituitary adenomas classified as 
partially responsive to somatostatin analog therapy. Eur J Endocrinol. 
53(1):135-41. 
56. Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, 
Moreau JP, Culler MD (2005) BIM-23A760, a chimeric molecule directed 
towards somatostatin and dopamine receptors, vs universal somatostatin 
receptors ligands in GH-secreting pituitary adenomas partial responders to 
octreotide. J Endocrinol Invest. 28(11 Suppl International):21-7. 
57. Bonger KM, van den Berg RJ, Knijnenburg AD, Heitman LH, van Koppen CJ, 
Timmers CM, Overkleeft HS, van der Marel GA (2009) Discovery of selective 
luteinizing hormone receptor agonists using the bivalent ligand method 
ChemMedChem.4(7):1189-95 
58. Bonger KM, Hoogendoorn S, van Koppen CJ, Timmers CM, van der Marel 
GA, Overkleeft HS (2010)  Development of Selective LH Receptor Agonists 
by Heterodimerization with a FSH Receptor Antagonist. ACS Med Chem Lett. 
8;2(1):85-9. 
 
 
 
19 
 
59.  Ayoub MA, Zhang Y, Kelly RS, See HB, Johnstone EK, McCall EA, Williams 
JH, Kelly DJ, Pfleger KD (2015) Functional interaction between angiotensin II 
receptor type 1 and chemokine (C-C motif) receptor 2 with implications for 
chronic kidney disease. PLoS ONE 10(3): e0119803 
60.  Agnes RS, Lee YS, Davis P, Ma SW, Badghisi H, Porreca F, Lai J, Hruby 
VJ.(2006) Structure-activity relationships of bifunctional peptides based on 
overlapping pharmacophores at opioid and cholecystokinin receptors. J Med 
Chem. 49(10):2868-75 
62. Yamamoto T, Nair P, Jacobsen NE, Davis P, Ma SW, Navratilova E, Moye S, 
Lai J, Yamamura HI, Vanderah TW, Porreca F, Hruby VJ (2008) The 
importance of micelle-bound states for the bioactivities of bifunctional peptide 
derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor 
antagonists. J Med Chem.51(20):6334-47 
63. Largent-Milnes TM, Brookshire SW, Skinner DP Jr, Hanlon KE, Giuvelis D, 
Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S, Bilsky EJ, Porreca 
F, Hruby VJ, Vanderah TW. (2013) Building a better analgesic: multifunctional 
compounds that address injury-induced pathology to enhance analgesic 
efficacy while eliminating unwanted side effects. J Pharmacol Exp Ther. 
347(1):7-19. 
64. Casadó V, Cortés A, Mallol J, Pérez-Capote K, Ferré S, Lluis C, Franco R, 
Canela EI. (2009) GPCR homomers and heteromers: a better choice as 
targets for drug development than GPCR monomers? Pharmacol Ther. 
124(2):248-57 
65. Sohy D, Yano H, de Nadai P, Urizar E, Guillabert A, Javitch JA, Parmentier M, 
Springael JY.(2009) Hetero-oligomerization of CCR2, CCR5, and CXCR4 and 
the protean effects of "selective" antagonists. J Biol Chem. 284(45):31270-9 
66.  Geng Y, Mosyak L, Kurinov I, Zuo H, Sturchler E, Cheng TC, Subramanyam 
P, Brown AP, Brennan SC, Mun HC, Bush M, Chen Y, Nguyen TX, Cao B, 
Chang DD, Quick M, Conigrave AD, Colecraft HM, McDonald P, Fan QR. 
(2016) Structural mechanism of ligand activation in human calcium-sensing 
receptor. Elife. 19;5. pii: e13662 
67.  Fotiadis D, Jastrzebska B, Philippsen A, Müller DJ, Palczewski K, Engel A. 
(2006) Structure of the rhodopsin dimer: a working model for G-protein-
coupled receptors. Curr Opin Struct Biol.16(2):252-9 
68 Huang J, Chen S, Zhang JJ, Huang XY (2013) Crystal structure of oligomeric 
β1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat 
Struct Mol Biol. 20(4):419-25 
69 Miao Y, McCammon JA. (2016) Graded activation and free energy 
landscapes of a muscarinic G-protein-coupled receptor. Proc Natl Acad Sci U 
S A. 113(43):12162-12167 
70. Staus DP, Strachan RT, Manglik A, Pani B, Kahsai AW, Kim TH, Wingler LM, 
Ahn S, Chatterjee A, Masoudi A, Kruse AC, Pardon E, Steyaert J, Weis WI, 
Prosser RS, Kobilka BK, Costa T, Lefkowitz RJ. (2016) Allosteric nanobodies 
reveal the dynamic range and diverse mechanisms of G-protein-coupled 
receptor activation. Nature. 535(7612):448-52 
 
 
 
20 
 
71.  DeVree BT, Mahoney JP, Vélez-Ruiz GA, Rasmussen SG, Kuszak AJ, 
Edwald E, Fung JJ, Manglik A, Masureel M, Du Y, Matt RA, Pardon E, 
Steyaert J, Kobilka BK, Sunahara RK. (2016) Allosteric coupling from G 
protein to the agonist-binding pocket in GPCRs. Nature. 535 (7610):182-6. 
72.  Ring AM, Manglik A, Kruse AC, Enos MD, Weis WI, Garcia KC, Kobilka BK. 
(2013) Adrenaline-activated structure of β2-adrenoceptor stabilized by an 
engineered nanobody. Nature. 502 (7472):575-9 
73. Maussang D, Mujić-Delić A, Descamps FJ, Stortelers C, Vanlandschoot P, 
Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo 
M, van Dongen GA, Merchiers P, van Rompaey P, Smit MJ. (2013) Llama-
derived single variable domains (nanobodies) directed against chemokine 
receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol 
Chem. 288(41):29562-72 
74. Nygaard R, Zou Y, Dror RO, Mildorf TJ, Arlow DH, Manglik A, Pan AC, Liu 
CW, Fung JJ, Bokoch MP, Thian FS, Kobilka TS, Shaw DE, Mueller L, 
Prosser RS, Kobilka BK. (2013)  The dynamic process of β(2)-adrenergic 
receptor activation. Cell. 152(3):532-42 
75. Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, Steyaert 
J, Rasmussen SG, Sunahara RK, El-Samad H, Huang B, von Zastrow M. 
(2013) Conformational biosensors reveal GPCR signalling from endosomes. 
Nature 495(7442):534-8 
76. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree 
BT, Rosenbaum DM, Thian FS, Kobilka TS, Schnapp A, Konetzki I, Sunahara 
RK, Gellman SH, Pautsch A, Steyaert J, Weis WI, Kobilka BK. (2011) 
Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. 
Nature. 469(7329):175-80. 
77. Gomes I, Gupta A, Bushlin I, Devi LA. (2014) Antibodies to probe 
endogenous G protein-coupled receptor heteromer expression, regulation, 
and function. Front Pharmacol. 3;5:268 
 
Highlights 
- Homo/heteromerization can diversify GPCR function 
- This article explores the in vitro and in vivo significance of GPCR heteromers, with 
focus on endocrine-related processes 
- This article describes the current outlook for pharmacological interventions and 
current/future treatment paradigms for GPCR heteromers.  
 
Highlights (for review)
GPCR Heteromer Endocrine system/axis References 
GHSR/MC3R Hypothalamic-gastrointestinal axis 25,26 
GHSR/D2R Hypothalamic-gastrointestinal axis 44 
GHSR/GPR83 Hypothalamic nuclei-metabolism 46 
GHSR/SST5a Insulinotropic action in pancreas 45 
GLP-1R/GIPR Insulinotropic action in pancreas 27 
LHR/FSHR Hypothalamic-pituitary-ovarian axis/ pre-ovulatory 
ovarian follicle 
39,40 
D4R/1BR Melatonin secretion from pineal gland 43 
D4R/1R Melatonin secretion from pineal gland 43 
AT1R/B2R Renin-angiotensin system in blood pressure 
regulation 
47,48 
V1bR/CRHR Hypothalamic-pituitary-adrenal axis/ adrenal 
chromaffin cells 
30 
D2R/SST2 Growth hormone-secreting pituitary tumors 53,54 
 
Table 1. Examples of G protein-coupled receptor (GPCR) heteromers that have been 
identified in distinct endocrine systems (see text). Abbreviations: 1B adrenergic receptors 
( 1BR); Angiotensin 1 receptor (AT1R); Beta1-adrenergic receptor (1R); Bradykinin 2 
receptor (B2R); Corticotrophin releasing hormone receptor (CRHR); Dopamine D2 receptor 
(D2R); Dopamine D4 receptor (D4R); Follicle stimulating hormone receptor (FSHR); Gastric-
inhibitory polypeptide receptor (GIPR); Growth hormone secretagogue receptor (GHSR); 
Glucagon-like peptide-1 receptor (GLP-1R); G protein-receptor 83 (GPR83); Luteinizing 
hormone receptor (LHR); Melanocortin-3 receptor (MC3R); somatostatin receptor 2 (SST2); 
somatostatin receptor 5a (SST5a); Vasopressin 1b receptor (V1bR) 
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